RxDoctor Payments Data

John Gray, MD

Family Medicine · Snoqualmie, WANPI 1770663759

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 39 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$362
  • Tris Pharma Inc$160
  • Novo Nordisk$151
  • Kowa Pharmaceuticals America, Inc.$72
  • Idorsia Pharmaceuticals US Inc$70
  • Shield Therapeutics Inc$60
  • plus $250 from 8 others

What the payments were for

  • Food & beverage$1,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$37,492
Medicare patients
80
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide63$66,988
EliquisApixaban44$39,494
OzempicSemaglutide33$37,434
XareltoRivaroxaban22$32,614
JardianceEmpagliflozin30$22,704
Combivent RespimatIpratropium/Albuterol Sulfate33$22,685
RybelsusSemaglutide12$11,433
Lisdexamfetamine Dimesylate15$6,403
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$2,813
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,782
Metoprolol Succinate156$2,609
Gabapentin105$2,378
Dextroamphetamine Sulfate40$2,166
Celecoxib96$1,768
Albuterol Sulfate HfaAlbuterol Sulfate67$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$43$66,98863 claims
Novo NordiskOzempic, Rybelsus$151$48,86745 claims
PfizerEliquis$21$39,49444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Snoqualmie

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →